GXO Logistics Inc vs Novartis AG — how do they compare? GXO Logistics Inc trades at $47.9 (market cap $5.37B), while Novartis AG trades at $152.62 (market cap $295.37B). The key difference: Novartis AG is far larger — about 55× GXO Logistics Inc's market cap, and Novartis AG pays a 3.07% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals.
| GXO | NVS | |
|---|---|---|
Market Cap | $5.37B | $295.37B |
Sector | Industrials | Health |
52-Week High | $65.59 | $168.62 |
52-Week Low | $45.52 | $119.31 |
Enterprise Value | $10.72B | $336.69B |
Dividend Yield | — | 3.07% |
Signals from Pluang's Aura AI — not financial advice
GXO Logistics trades at $47.85, up 1.9% in the last session, with a bearish technical signal but strong analyst backing. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.59 exceeding expectations, and revenue growth to $13.6 billion in 2026. However, margins remain tight, with a net income margin of 0.96%, and the P/E ratio of 41.3 suggests high valuation relative to earnings.
The outlook is mixed: bullish analyst consensus, with 88.9% buy ratings and a $65.67 price target, indicates potential upside, but stagnant margins and bearish technicals pose risks. Investors should weigh strong business wins against cost absorption challenges highlighted in recent earnings reports.
Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.
The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.
Trailing returns across standard periods
Latest headlines on both assets
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →